COMP <GO>
SPRO vs MRK // PIOTROSKI F-SCORE QUALITY
Spero Therapeutics Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: SPRO 6
— MRK 6
▲ PIOTROSKI F-SCORE QUALITY LEADER: MRK
LAST: $1.06 (-4.50%) • MKT CAP: $64.6M
piotroski-score
5/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SPRO VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SPRO | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 26.60% | 20.70% | +5.90 | SPRO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.1x | 15.3x | -10.20 | SPRO | /valuation <GO> |
| Free Cash Flow Yield | -19.53% | 3.42% | -22.95 | MRK | /fcf-yield <GO> |
| Operating Margin | 50.20% | 34.30% | +15.90 | SPRO | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.10% | +39.90 | SPRO | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 1.30% | +178.70 | SPRO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.19 | -4.99 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.2 | 51.7 | -10.51 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.3x | 18.4x | -12.10 | SPRO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $64.6M | $361.02B | -$360.96B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SPRO REV | MRK REV | SPRO GROSS % | MRK GROSS % | SPRO FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.6M | $65.01B | — | 74.8% | -$12.6M | $12.36B |
| FY 2024 | $371.0K | $64.17B | — | 76.3% | -$23.4M | $18.10B |
| FY 2023 | $933.0K | $60.12B | — | — | -$33.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SPRO // BETA —
MRK // BETA 0.92